High Dose of Intravenous Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells (CLV-100) Infusion Displays Better Immunomodulatory Effect among Healthy Volunteers: A Phase 1 Clinical Study
Background. Mesenchymal stem cells (MSCs) express growth factors and other cytokines that stimulate repair and control the immune response. MSCs are also immunoprivileged with low risk of rejection. Umbilical cord-derived MSCs (UCMSCs) are particularly attractive as an off-the-shelf allogeneic treat...
Saved in:
| Main Authors: | Sze-Piaw Chin, Mohd-Yusoff Mohd-Shahrizal, Mohd-Zuhar Liyana, Kong Yong Then, Soon Keng Cheong |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2020/8877003 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Introducing a Novel Model to Determine CLV
by: Jafar Razmi, et al.
Published: (2009-03-01) -
Blockchain-enabled KYC integration for CLV optimization with robust M-Estimation and IRLS method
by: Marischa Elveny, et al.
Published: (2025-06-01) -
Umbilical Cord-Derived Mesenchymal Stem Cells Infusion in Type 2 Diabetes Mellitus Patients: A Retrospective Cytopeutics’ Registry Study
by: Chin SP, et al.
Published: (2025-05-01) -
How can Artificial Intelligence (AI) be used to manage Customer Lifetime Value (CLV)—A systematic literature review
by: Edo Belva Firmansyah, et al.
Published: (2024-11-01) -
Clinical trial to compare safety and tolerability between intravenous infusion and bolus intravenous injection of ApTOLL in healthy volunteers
by: Macarena Hernández-Jiménez, et al.
Published: (2025-03-01)